Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Description:

For complete information, please view the study at clinicaltrials.gov

Study Status:

Closed

Study Sponsor:

Children's Oncology Group

Full IRB Study Title:

Phase II Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

IRB Study ID:

150914

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...